Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Published:2020-12-01 Issue:2 Volume:60 Page:157-164
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Brems-Eskildsen Anne Sofie¹,Linnet Søren²,Danø Hella³,Luczak Adam⁴,Vestlev Peter Michael⁵,Jakobsen Erik Hugger⁶,Neimann Jeppe¹,Jensen Charlotte Buch¹,Dongsgaard Trine²,Langkjer Sven Tyge¹

Affiliation:

1. Department of Oncology, University Hospital of Aarhus, Aarhus, Denmark

2. Department of Oncology, Region Hospital of West Jutland, Herning, Denmark

3. Department of Oncology, Region Hospital in Hilleroed, Hillerod, Denmark

4. Department of Oncology, University Hospital of Aalborg, Aalborg, Denmark

5. Department of Oncology, Roskilde Hospital, Roskilde, Denmark

6. Department of Oncology, Region Hospital in Esbjerg, Esbjerg, Denmark

Funder

Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning

Les Laboratories Pierre Fabre

Radiumstationesforskningsfond, Aarhus Univestites Hospital

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1851045

Reference37 articles.

1. Breast cancer

2. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

3. Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts

4. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

5. The anti-angiogenic basis of metronomic chemotherapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy;Frontiers in Cell and Developmental Biology;2024-05-15

2. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study;The Breast;2024-04

3. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer;Thoracic Cancer;2023-07-04

4. Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study;Breast Care;2023

5. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows;Journal of Clinical Medicine;2022-08-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3